Prostate cancer tumor grade differentiation with dynamic contrast- enhanced MR imaging in the rat: Comparison of macromolecular and small- molecular contrast media - Preliminary experience

Radiology

Volumn 213, Issue 1, 1999, Pages 265-272

  Gossmann, Axel ^a   Okuhata, Yoshitaka ^a   Shames, David M ^a   Helbich, Thomas H ^a   Roberts, Timothy P L ^a   Wendland, Michael F ^a   Huber, Sabine ^a   Brasch, Robert C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gadolinium; Magnetic resonance (MR), contrast media; Prostate, MR; Prostate, neoplasms

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE ALBUMIN; PENTETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER GRADING; COMPARTMENT MODEL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE CLASSIFICATION; HISTOPATHOLOGY; IMAGE ANALYSIS; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; RAT;

EID: 0032888214     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.213.1.r99oc43265     Document Type: Article

References (45)

1. American Cancer Society. Facts and figures, 1994. Atlanta, Ga: American Cancer Society, 1994.
2. Rich AR. On the frequency of occurrence of occult carcinoma of the prostate. J Urol 1935; 33:215-223.
3. Silverberg E, Lubera JA. Cancer statistics. Cancer 1988; 38:15-22.
4. Quinlan DM, Partin AW, Walsh PC. Can aggressive prostatic carcinomas be identified and can their natural history be altered by treatment? Urology 1995; 46(suppl A):77-82.
5. Catalona W. Surgical management of prostate cancer: contemporary results with anatomic radical prostatectomy. Cancer 1995; 75:1903-1908.
6. Chodak GW, Trusted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330:242-248.
7. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993; 269:2650-2658.
8. Johansson JE, Adami HO, Andersson SO, Bergström R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992; 267:2191-2196.
9. Epstein JI, Carmichael M, Walsh PC. Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis. J Urol 1993; 149:1040-1045.
10. Yu KK, Hricak H, Alagappan R, Chernoff DM, Bacchetti P, Zaloudek CJ. Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology 1997; 202:697-702.
11. Mills SE, Fowler JE. Gleason histologic grading of prostatic carcinoma: correlation between biopsy and prostatectomy specimens. Cancer 1986; 57:346-349.
12. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133:95-109.
13. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986; 31:288-305.
14. Isaacs JT, Hukku B. Nonrandom involvement of chromosome 4 in the progression of rat prostatic cancer. Prostate 1988; 13: 165-188.
15. Isaacs JT, Yu G, Coffey DS. The characterization of a newly identified, highly metastatic variant of the Dunning R-3327 rat prostatic adenocarcinoma system: the MAT-LyLu tumor. Invest Urol 1981; 19: 20-23.
16. Voigt P, Lopez DM. Characterization of prostate carcinoma lines in the Copenhagen rat. Natl Cancer Inst Monogr 1978; 49:269-273.
17. Weinmann HJ, Brasch RC, Press WR, Wesbey GE. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR 1984; 142:619-624.
18. Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984; 16:167-172.
19. Ogan MD, Schmiedl U, Moseley ME, Grodd W, Paajanen H, Brasch RC. Albumin labeled with Gd-DTPA: an intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. Invest Radiol 1987; 22:665-671.
20. Schmiedl U, Ogan MD, Moseley ME, Brasch RC. Comparison of the contrast-enhancing properties of albumin-(Gd-DTPA) and Gd-DTPA at 2.0 T: an experimental study in rats. AJR 1986; 147:1263-1270.
21. Jones RA, Haraldseth O, Müller TB, Rinck PA, Øksendal AN. K-space substitution: a novel dynamic imaging technique. Magn Reson Med 1993; 29:830-834.
22. van Vaals JJ, Brummer ME, Dixon WT, et al. "Keyhole" method for accelerating imaging of contrast agent uptake. J Magn Reson Med 1993; 3:671-675.
23. Schwickert HC, Roberts TP, Shames DM, et al. Quantification of liver blood volume: comparison of ultra short T1 inversion recovery echo planar imaging (ULSTIR-EPI), with dynamic 3D-gradient recalled echo imaging. Magn Reson Med 1995; 34:845-852.
24. Roberts TPL, Brasch RC, Schwickert HC, et al. Quantification of tissue gadolinium concentration using magnetic resonance imaging: comparison of ultrashort inversion time inversion recovery echoplanar and three-dimensional spoiled gradient-recalled approaches with in vitro measurements. Acad Radiol 1996; 3:282-285.
25. Bloembergen N, Purcell EM, Pound RV. Principles of nuclear relaxation. Phys Rev 1948; 73:679-712.
26. Koenig SH, Spiller M, Brown RD, Wolf GL. Relaxation of water protons in the intra- and extracellular regions of blood containing Gd(DTPA). Magn Reson Med 1986; 3:791-795.
27. Daldrup HE, Shames DM, Wendland M, et al. Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR 1998; 171:941-949.
28. Kuwatsuru R, Shames DM, Mühler A, et al. Quantification of tissue plasma volume in the rat by contrast-enhanced magnetic resonance imaging. Magn Reson Med 1993; 30:76-81.
29. Jager GJ, Barentz JO, Ruijter ETG, de la Rosette JJMCH, Oosterhof GON. Primary staging of prostate cancer. Eur Radiol 1996; 6:134-139.
30. Hricak H, Bree RL, Cohan R, et al. Genitourinary radiology. Radiology 1996; 198: 603-612.
31. Huch Böni RA, Boner JA, Lütolf UM, Trinkler F, Pestalozzi DM, Krestin GP. Contrast-enhanced endorectal coil MRI in local staging of prostate carcinoma. J Comput Assist Tomogr 1995; 19:232-237.
32. Mirowitz SA, Brown JJ, Heiken JP. Evaluation of the prostate and prostatic carcinoma with gadolinium-enhanced endorectal coil MR imaging. Radiology 1993; 186:153-157.
33. Sommer FG, Nghiem HV, Herfkens R, McNeal J. Gadolinium-enhanced MRI of the abnormal prostate. Magn Reson Imaging 1993; 11:941-948.
34. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AGJ, Wennberg JE. A structured literature review of treatment for localized prostate cancer. Arch Fam Med 1993; 2:487-493.
35. Shames DM, Kuwatsuru R, Vexler V, Muhler A, Brasch RC. Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique. Magn Reson Med 1993; 29:616-622.
36. Garnett JE, Oyasu R, Grayhack JT. The accuracy of diagnostic biopsy specimens in predicting tumor grades by Gleason's classification of radical prostatectomy specimens. J Urol 1984; 131:690-693.
37. Lange PH, Narayan P. Understaging and undergrading of prostate cancer. Urology 1983; 21:113-118.
38. Jager GJ, Ruijter ET, van de Kaa CA, et al. Dynamic turboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 1997; 203: 645-652.
39. Quinn SF, Franzini DA, Demlow TA, et al. MR imaging of prostate cancer with an endorectal surface coil technique: correlation with whole-mount specimens. Radiology 1994; 190:323-327.
40. Brown G, Macvicar DA, Ayton V, Husband JE. The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma. Clin Radiol 1995; 50:601-606.
41. Huch Boni RA, Boner JA, Debatin JF, et al. Optimization of prostate carcinoma staging: comparison of imaging and clinical methods. Clin Radiol 1995; 50:593-600.
42. Vigneron DB, Males R, Noworolski S, et al. 3D MRSI of prostate cancer: correlation with histologic grade (abstr). In: Proceedings of the Sixth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 1998; 488.
43. Schwickert HC, Stiskal M, van Dijke CF, et al. Tumor angiography using high resolution 3D MRI: comparison of Gd-DTPA and a macromolecular blood pool contrast agent. Acad Radiol 1995; 2:851-858.
44. Schwickert HC, Roberts TPL, Mühler A, Stiskal M, Demsar F, Brasch RC. Angiographic properties of Gd-DTPA-24-cascade-polymer a new macromolecular MR contrast agent. Eur Radiol 1995; 20:144-150.
45. Lauffer RB, Parmelee DJ, Quellet HS, et al. MS-325: a small-molecule vascular imaging agent for magnetic resonance imaging. Acad Radiol 1996; 3:356-358.